Zynerba Pharmaceuticals, Inc.
Built from real-time financials and updated daily. For a full Analyst Grade with bull/bear case, price targets, and qualitative risk analysis, generate a ZYNE research report →
Companywww.zynerba.com
Zynerba Pharmaceuticals, Inc. operates as a clinical stage specialty pharmaceutical company. The company focuses on developing pharmaceutically-produced transdermal cannabinoid therapies for rare and near-rare neuropsychiatric disorders.
- CEO
- Armando Anido MBA
- IPO
- 2015
- Employees
- 25
- HQ
- Devon, PA, US
Price Chart
Valuation
- Market Cap
- $70.12M
- P/E
- -1.59
- P/S
- 0.00
- P/B
- 1.20
- EV/EBITDA
- -0.57
- Div Yield
- 0.00%
Profitability
- Gross Margin
- 0.00%
- Op Margin
- 0.00%
- Net Margin
- 0.00%
- ROE
- -59.45%
- ROIC
- -75.24%
Growth & Income
- Revenue
- $0 · 0.00%
- Net Income
- $-34,820,072 · 7.39%
- EPS
- $-0.82 · 14.58%
- Op Income
- $-35,251,540
- FCF YoY
- 30.81%
Performance & Tape
- 52W High
- $1.40
- 52W Low
- $0.25
- 50D MA
- $1.12
- 200D MA
- $0.61
- Beta
- 1.19
- Avg Volume
- 1.04M
Get TickerSpark's AI analysis on ZYNE
Pro members can request AI-generated analysis on any ticker — technical setup, analyst consensus, earnings watch, insider pulse, financial health, and peer context. Ready in about a minute.
Get Pro Access →30-day money-back guarantee · cancel anytime
Recent Insider Transactions
| Date | Insider | Type | Shares |
|---|---|---|---|
| Oct 10, 23 | Jones Kenneth T | other | 30,000 |
| Oct 10, 23 | Jones Kenneth T | other | 40,520 |
| Oct 10, 23 | Jones Kenneth T | other | 75,000 |
| Oct 10, 23 | Jones Kenneth T | sell | 21,250 |
| Oct 10, 23 | Stephenson Pamela | other | 27,954 |
| Oct 10, 23 | Stephenson Pamela | sell | 71,736 |
| Oct 10, 23 | Stephenson Pamela | other | 47,824 |
| Oct 10, 23 | Stephenson Pamela | sell | 34,663 |
| Oct 10, 23 | Fickenscher James E | other | 170,000 |
| Oct 10, 23 | Fickenscher James E | other | 123,087 |
Our ZYNE Coverage
We haven't published any research on ZYNE yet
For a full analyst-grade research report — grades, price targets, full financials, chart analysis — generate one on demand.
Generate ZYNE Report →